BMY
Bristol-Myers Squibb Co.
$67.02
장중 · Vol 170.9K · 52주 $42.52–$68.64 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $66.07 · Aug 31, 2026
BMY 가격 추세
종가
$66.07
시가
$66.77
고가
$66.25
저가
$65.93
30초 브리핑
BMY 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 94%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E 10.2배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.0배
거래량은 최근 평균 범위입니다.
2026-10-29
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
BMY 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Route 206 & Province Line Road · Princeton, NJ, United States · 직원 32,500명
시가총액
$136.47B
Trailing P/E
14.7
최근 12개월 이익 기준
Forward P/E
10.2
이익 증가 기대 반영
EPS (TTM)
$4.56
배당 수익률
3.78%
배당성향
55.3%
베타
0.23
시장보다 방어적
ROE
46.6%
P/B
6.12
EV/EBITDA
9.0
52주 범위
$42.52 – $68.64
현재 위치 94%
거래량
6.83M
20일 평균 7.10M · 1.0배
애널리스트 의견
매수 36%
총 28명 · 0m
DITM LEAPS Analysis
BMY 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY280121C00043000 | 1/21/28 · 1.4Y | $43.00 | $24.92 | 2.4x | 0.9098 | 4.5% | 7.82% | 38.33% | 160 | 90.37 | |
| BMY280121C00047000 | 1/21/28 · 1.4Y | $47.00 | $21.38 | 2.8x | 0.8886 | 7.3% | 8.19% | 34.62% | 241 | 88.24 | |
| BMY280121C00035000 | 1/21/28 · 1.4Y | $35.00 | $32.00 | 1.9x | 0.9198 | 0.6% | 15.63% | 56.06% | 64 | 86.69 | |
| BMY271217C00035000 | 12/17/27 · 1.3Y | $35.00 | $32.00 | 1.9x | 0.9188 | 0.6% | 15.63% | 58.09% | 88 | 86.57 | |
| BMY271217C00050000 | 12/17/27 · 1.3Y | $50.00 | $18.78 | 3.0x | 0.8578 | 10.5% | 12.52% | 35.16% | 816 | 83.88 | |
| BMY270917C00050000 | 9/17/27 · 1.0Y | $50.00 | $18.53 | 3.1x | 0.8657 | 9.3% | 8.91% | 35.67% | 32 | 83.01 | |
| BMY280121C00050000 | 1/21/28 · 1.4Y | $50.00 | $18.85 | 3.0x | 0.8570 | 10.8% | 13.26% | 34.65% | 481 | 82.97 | |
| BMY271217C00045000 | 12/17/27 · 1.3Y | $45.00 | $23.25 | 2.5x | 0.8701 | 6.2% | 19.35% | 46.13% | 886 | 82.61 | |
| BMY280121C00045000 | 1/21/28 · 1.4Y | $45.00 | $23.50 | 2.5x | 0.8647 | 7.2% | 21.28% | 47.14% | 284 | 79.72 | |
| BMY271217C00052500 | 12/17/27 · 1.3Y | $52.50 | $17.30 | 3.2x | 0.8305 | 17.3% | 9.83% | 34.68% | 131 | 77.26 | |
| BMY280121C00052500 | 1/21/28 · 1.4Y | $52.50 | $17.75 | 3.1x | 0.8206 | 19.4% | 12.96% | 36.72% | 355 | 74.90 | |
| BMY280121C00055000 | 1/21/28 · 1.4Y | $55.00 | $15.97 | 3.4x | 0.7999 | 26.1% | 9.08% | 34.05% | 196 | 71.14 | |
| BMY271217C00055000 | 12/17/27 · 1.3Y | $55.00 | $15.90 | 3.3x | 0.7928 | 25.7% | 13.84% | 36.54% | 148 | 68.42 | |
| BMY270917C00055000 | 9/17/27 · 1.0Y | $55.00 | $15.08 | 3.6x | 0.8024 | 21.7% | 10.28% | 35.28% | 1 | 67.73 | |
| BMY280121C00057500 | 1/21/28 · 1.4Y | $57.50 | $14.28 | 3.6x | 0.7700 | 34.8% | 10.16% | 33.20% | 164 | 64.23 | |
| BMY271217C00057500 | 12/17/27 · 1.3Y | $57.50 | $13.95 | 3.6x | 0.7608 | 33.3% | 22.94% | 36.55% | 185 | 59.81 |
재무제표
BMY 연간 손익·현금흐름·재무상태
매출 성장률
-0.2%
최근 연간 YoY
EPS 성장률
+178.5%
최근 연간 YoY
영업이익률
28.5%
최근 연간
FCF 마진
26.7%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $48.20B-0.2% | $48.30B+7.3% | $45.01B-2.5% | $46.16B |
| 매출총이익 | $34.26B-0.2% | $34.33B+0.1% | $34.31B-4.7% | $36.02B |
| 영업이익 | $13.72B+133.1% | $5.89B-28.2% | $8.20B-10.0% | $9.10B |
| 순이익 | $7.05B+178.8% | -$8.95B-211.5% | $8.03B+26.8% | $6.33B |
| 희석 EPS | $3.46+178.5% | $-4.41-214.2% | $3.86+30.8% | $2.95 |
| EBITDA | $15.23B+380.7% | $3.17B-83.6% | $19.37B+0.8% | $19.22B |
| 영업현금흐름 | $14.16B-6.8% | $15.19B+9.6% | $13.86B+6.1% | $13.07B |
| 잉여현금흐름 | $12.85B-7.9% | $13.94B+10.2% | $12.65B+5.9% | $11.95B |
| 총자산 | $90.04B-2.8% | $92.60B-2.7% | $95.16B-1.7% | $96.82B |
| 총부채 | $47.14B-7.9% | $51.20B+23.5% | $41.46B+1.8% | $40.72B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
BMY 실적·배당 일정
매출 하단
$12.28B
EPS 하단
$1.59
매출 상단
$13.06B
배당 지급일
2026-08-03
29일 전
실적 발표일
2026-10-29
D-58
EPS 상단
$1.92
매출 컨센서스
$12.66B
EPS 컨센서스
$1.73
배당락일
2026-07-02
61일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Jul 2, 2026 | $0.6300 |
| Apr 2, 2026 | $0.6300 |
| Jan 2, 2026 | $0.6300 |
| Oct 3, 2025 | $0.6200 |
| Jul 3, 2025 | $0.6200 |
| Apr 4, 2025 | $0.6200 |
| Jan 3, 2025 | $0.6200 |
| Oct 4, 2024 | $0.6000 |
뉴스
BMY 관련 최신 기사
일반Novartis Pauses Autoimmune Cell Therapy Studies After Deaths
Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died.
The Wall Street Journal · Sep 1, 2026
주주환원This Popular Healthcare ETF Is Diluting Your Dividend Income
XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.
24/7 Wall St. · Aug 31, 2026
- 일반
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers to voluntarily pause its zola-cel program.
BioPharma Dive · Aug 31, 2026
제품·기술3 Reasons to Sell BMY and 1 Stock to Buy Instead
Even though Bristol-Myers Squibb (currently trading at $66.44 per share) has gained 6.6% over the last six months, it has lagged the S&P 500’s 12.3% return during that period. This might have investors contemplating their next move.
StockStory · Aug 31, 2026
- 일반
Cocrystal Pharma: The Strategic Reset Investors May Be Missing
By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.
Exec Edge · Aug 31, 2026
- 제품·기술
Jefferies starts biopharma firm Braveheart at Buy after IPO
Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.
Investing.com · Aug 31, 2026
일반Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.
Motley Fool · Aug 29, 2026
실적Bristol Myers Squibb (BMY) Stock Looks Reasonable On Earnings Yet Strong Returns Test Value
Bristol-Myers Squibb has delivered a strong 47.9% return over the past year, yet several valuation checks still frame the stock as cheap relative to an intrinsic value estimate and to market multiples. For investors, the question is whether the current share price reflects a genuine discount or simply the market catching up with earlier pessimism. The 47.9% gain over 1 year highlights how sharply sentiment toward Bristol-Myers Squibb has improved. This can reduce the margin of safety if...
Simply Wall St. · Aug 29, 2026
제품·기술Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb
CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients. Several approved therapies have delivered strong responses for patients with advanced blood cancers where conventional treatments have failed. It’s no wonder the CAR-T market is expanding rapidly. The global CAR-T therapy market is projected to grow from $2.69 billion in 2022 to […]
Insider Monkey · Aug 29, 2026
일반Cytokinetics Boasts A First-Ever In Heart Disease — And Shares Drop
Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday.
Investor's Business Daily · Aug 28, 2026
홀더
BMY 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
84.7%
기관 보유 (유동주식)
84.8%
내부자 보유
0.1%
기관 수
3,268
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 180.38M | $12.05B | 8.8% | 5.1% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 133.34M | $8.91B | 6.5% | 0.8% | Jun 30, 2026 |
| State Street Corporation | 102.41M | $6.84B | 5.0% | 3.9% | Jun 30, 2026 |
| JPMORGAN CHASE & CO | 71.71M | $4.79B | 3.5% | -22.4% | Jun 30, 2026 |
| Charles Schwab Investment Management, Inc. | 67.60M | $4.52B | 3.3% | 10.6% | Jun 30, 2026 |
| Geode Capital Management, LLC | 56.44M | $3.77B | 2.8% | 2.1% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 46.87M | $3.13B | 2.3% | 1.4% | Jun 30, 2026 |
| NORGES BANK | 36.87M | $2.46B | 1.8% | 2.1% | Jun 30, 2026 |
| Bank of America Corporation | 34.05M | $2.27B | 1.7% | 4.5% | Jun 30, 2026 |
| Price (T.Rowe) Associates Inc | 31.71M | $2.12B | 1.6% | 209.3% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.